The Influence of Nicotinamide on Health and Disease in the Central Nervous System

Nicotinamide, the amide form of vitamin B3 (niacin), has long been associated with neuronal development, survival, and function in the central nervous system (CNS), being implicated in both neuronal death and neuroprotection. Here, we summarise a body of research investigating the role of nicotinamide in neuronal health within the CNS, with a focus on studies that have shown a neuroprotective effect. Nicotinamide appears to play a role in protecting neurons from traumatic injury, ischaemia, and stroke, as well as being implicated in 3 key neurodegenerative conditions: Alzheimer’s, Parkinson’s, and Huntington’s diseases. A key factor is the bioavailability of nicotinamide, with low concentrations leading to neurological deficits and dementia and high levels potentially causing neurotoxicity. Finally, nicotinamide’s potential mechanisms of action are discussed, including the general maintenance of cellular energy levels and the more specific inhibition of molecules such as the nicotinamide adenine dinucleotide-dependent deacetylase, sirtuin 1 (SIRT1).

[1]  J. Auwerx,et al.  Modulating NAD+ metabolism, from bench to bedside , 2017, The EMBO journal.

[2]  M. Pickard,et al.  Nicotinamide alone accelerates the conversion of mouse embryonic stem cells into mature neuronal populations , 2017, PloS one.

[3]  R. Zhai,et al.  NMNAT: It's an NAD+ synthase… It's a chaperone… It's a neuroprotector. , 2017, Current opinion in genetics & development.

[4]  Timothy A. Blenkinsop,et al.  Nicotinamide Ameliorates Disease Phenotypes in a Human iPSC Model of Age-Related Macular Degeneration. , 2017, Cell stem cell.

[5]  Zachary B. Loris,et al.  The neuroprotective compound P7C3-A20 promotes neurogenesis and improves cognitive function after ischemic stroke , 2017, Experimental Neurology.

[6]  Michael J. Phelan Phase II Clinical Trial of Nicotinamide for the Treatment of Mild to Moderate Alzheimer's Disease , 2017 .

[7]  Robert A. Smith,et al.  Quinolinic acid induces neuritogenesis in SH‐SY5Y neuroblastoma cells independently of NMDA receptor activation , 2017, The European journal of neuroscience.

[8]  M. Z. Cader,et al.  Mitophagy and Alzheimer’s Disease: Cellular and Molecular Mechanisms , 2017, Trends in Neurosciences.

[9]  Pete A. Williams,et al.  Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice , 2017, Science.

[10]  K. P. Kepp,et al.  Ten Challenges of the Amyloid Hypothesis of Alzheimer's Disease. , 2016, Journal of Alzheimer's disease : JAD.

[11]  M. Hayden,et al.  Comparative Mitochondrial-Based Protective Effects of Resveratrol and Nicotinamide in Huntington’s Disease Models , 2017, Molecular Neurobiology.

[12]  S. Ito,et al.  Nicotinamide benefits both mothers and pups in two contrasting mouse models of preeclampsia , 2016, Proceedings of the National Academy of Sciences.

[13]  Mark S. Schmidt,et al.  Nicotinamide riboside is uniquely and orally bioavailable in mice and humans , 2016, Nature Communications.

[14]  J. Reid,et al.  CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. , 2016, Cell metabolism.

[15]  D. Bennett,et al.  NMNAT2:HSP90 Complex Mediates Proteostasis in Proteinopathies , 2016, PLoS biology.

[16]  J. Milbrandt,et al.  Axon Self-Destruction: New Links among SARM1, MAPKs, and NAD+ Metabolism , 2016, Neuron.

[17]  E. Verdin NAD+ in aging, metabolism, and neurodegeneration , 2015, Science.

[18]  Aimin Liu,et al.  What is the tryptophan kynurenine pathway and why is it important to neurotherapeutics? , 2015, Expert review of neurotherapeutics.

[19]  J. Morgan,et al.  Low-dose niacin supplementation modulates GPR109A, niacin index and ameliorates Parkinson’s disease symptoms without side effects , 2015, Clinical case reports.

[20]  James W. MacDonald,et al.  A Combination Therapy of Nicotinamide and Progesterone Improves Functional Recovery following Traumatic Brain Injury. , 2015, Journal of neurotrauma.

[21]  N. Narayanan,et al.  Protective efficacy of P7C3-S243 in the 6-hydroxydopamine model of Parkinson's disease , 2015, npj Parkinson's Disease.

[22]  J. Milbrandt,et al.  SARM1 activation triggers axon degeneration locally via NAD+ destruction , 2015, Science.

[23]  Anil Kumar,et al.  A review on Alzheimer’s disease pathophysiology and its management: an update , 2015, Pharmacological reports : PR.

[24]  F. Giorgini,et al.  The kynurenine pathway and neurodegenerative disease. , 2015, Seminars in cell & developmental biology.

[25]  Aaron Long,et al.  Effect of nicotinamide mononucleotide on brain mitochondrial respiratory deficits in an Alzheimer’s disease-relevant murine model , 2015, BMC Neurology.

[26]  Kamil Ugurbil,et al.  In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences , 2015, Proceedings of the National Academy of Sciences.

[27]  J. Cannon,et al.  Dietary Factors in the Etiology of Parkinson's Disease , 2015, BioMed research international.

[28]  R. Ribchester,et al.  A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration , 2014, Cell Death and Differentiation.

[29]  J. Morgan,et al.  Upregulation of GPR109A in Parkinson’s Disease , 2014, PloS one.

[30]  E. Koylu,et al.  Ex vivo protective effects of nicotinamide and 3‐aminobenzamide on rat synaptosomes treated with Aβ(1–42) , 2014, Cell biochemistry and function.

[31]  S. McKnight,et al.  P7C3 Neuroprotective Chemicals Function by Activating the Rate-Limiting Enzyme in NAD Salvage , 2014, Cell.

[32]  J. Gilley,et al.  Wallerian degeneration: an emerging axon death pathway linking injury and disease , 2014 .

[33]  Jose A. Santiago,et al.  The emerging role of nutrition in Parkinson's disease , 2014, Front. Aging Neurosci..

[34]  Qingtao Wang,et al.  Overexpression of CD38 decreases cellular NAD levels and alters the expression of proteins involved in energy metabolism and antioxidant defense. , 2014, Journal of proteome research.

[35]  D. Turner,et al.  Nicotinamide pre-treatment ameliorates NAD(H) hyperoxidation and improves neuronal function after severe hypoxia , 2014, Neurobiology of Disease.

[36]  E. Koylu,et al.  Nicotinamide treatment reduces the levels of oxidative stress, apoptosis, and PARP-1 activity in Aβ(1–42)-induced rat model of Alzheimer's disease , 2014, Free radical research.

[37]  Abbas Ali Mahdi,et al.  Therapeutics of Alzheimer's disease: Past, present and future , 2014, Neuropharmacology.

[38]  A. Keshavarzian,et al.  Nutrition and Gastrointestinal Health as Modulators of Parkinson’s Disease , 2014 .

[39]  R. Diem,et al.  Dysfunction of neuronal calcium signalling in neuroinflammation and neurodegeneration , 2013, Cell and Tissue Research.

[40]  P. Sachdev,et al.  Mapping NAD+ metabolism in the brain of ageing Wistar rats: potential targets for influencing brain senescence , 2014, Biogerontology.

[41]  E. Mercken,et al.  Declining NAD+ Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during Aging , 2013, Cell.

[42]  M. Pickard,et al.  Nicotinamide promotes neuronal differentiation of mouse embryonic stem cells in vitro , 2013, Neuroreport.

[43]  A. Sauve,et al.  Nicotinamide riboside, a trace nutrient in foods, is a Vitamin B3 with effects on energy metabolism and neuroprotection , 2013, Current opinion in clinical nutrition and metabolic care.

[44]  G. Pasinetti,et al.  Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-γ coactivator 1α regulated β-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models , 2013, Neurobiology of Aging.

[45]  M. Mattson,et al.  Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: evidence for improved neuronal bioenergetics and autophagy procession , 2013, Neurobiology of Aging.

[46]  J. López-Miranda,et al.  Endothelial Aging Associated with Oxidative Stress Can Be Modulated by a Healthy Mediterranean Diet , 2013, International journal of molecular sciences.

[47]  J. Milbrandt,et al.  Protection of mouse retinal ganglion cell axons and soma from glaucomatous and ischemic injury by cytoplasmic overexpression of Nmnat1. , 2013, Investigative ophthalmology & visual science.

[48]  K. Shibata,et al.  Nutritional Aspect of Tryptophan Metabolism , 2013, International journal of tryptophan research : IJTR.

[49]  K. Kraemer,et al.  Introduction: The Diverse and Essential Biological Functions of Vitamins , 2012, Annals of Nutrition and Metabolism.

[50]  S. McKnight,et al.  Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis , 2012, Proceedings of the National Academy of Sciences.

[51]  R. Semba The discovery of the vitamins. , 2012, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.

[52]  G. Donmez The neurobiology of sirtuins and their role in neurodegeneration. , 2012, Trends in pharmacological sciences.

[53]  N. Braidy,et al.  Age-Associated Changes In Oxidative Stress and NAD+ Metabolism In Human Tissue , 2012, PloS one.

[54]  Adrian C. Williams,et al.  Nicotinamide, NAD(P)(H), and Methyl-Group Homeostasis Evolved and Became a Determinant of Ageing Diseases: Hypotheses and Lessons from Pellagra , 2012, Current gerontology and geriatrics research.

[55]  Efsa Panel on Dietetic Products Scientific Opinion on Dietary Reference Values for iodine. , 2014 .

[56]  R. Zhai,et al.  CREB-activity and nmnat2 transcription are down-regulated prior to neurodegeneration, while NMNAT2 over-expression is neuroprotective, in a mouse model of human tauopathy. , 2012, Human molecular genetics.

[57]  B. Barres,et al.  Axon degeneration: Molecular mechanisms of a self-destruction pathway , 2012, The Journal of cell biology.

[58]  J. Toldi,et al.  Altered tryptophan metabolism in Parkinson's disease: A possible novel therapeutic approach , 2011, Journal of the Neurological Sciences.

[59]  C. V. Haar,et al.  Continuous nicotinamide administration improves behavioral recovery and reduces lesion size following bilateral frontal controlled cortical impact injury , 2011, Behavioural Brain Research.

[60]  A. Blokland,et al.  Liver X receptor activation restores memory in aged AD mice without reducing amyloid , 2011, Neurobiology of Aging.

[61]  P. Kusumanchi,et al.  NMNAT expression and its relation to NAD metabolism. , 2011, Current medicinal chemistry.

[62]  A. Messer,et al.  Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease , 2011, Neurobiology of Disease.

[63]  Jing Wang,et al.  Inhibition of Sirt1 promotes neural progenitors toward motoneuron differentiation from human embryonic stem cells. , 2011, Biochemical and biophysical research communications.

[64]  Jing Wang,et al.  Inhibition of Sirt 1 promotes neural progenitors toward motoneuron differentiation from human embryonic stem cells , 2011 .

[65]  M. Chopp,et al.  Niacin, an Old Drug, has New Effects on Central Nervous System Disease , 2010 .

[66]  G. Torres,et al.  Distribution Analysis of Deacetylase SIRT1 in Rodent and Human Nervous Systems , 2010, Anatomical record.

[67]  Adriana B Ferreira,et al.  Increased Membrane Cholesterol Might Render Mature Hippocampal Neurons More Susceptible to β-Amyloid-Induced Calpain Activation and Tau Toxicity , 2009, The Journal of Neuroscience.

[68]  D. Dougherty,et al.  L-Tryptophan: Basic Metabolic Functions, Behavioral Research and Therapeutic Indications , 2009, International journal of tryptophan research : IJTR.

[69]  N. Braidy,et al.  Promotion of cellular NAD+ anabolism: Therapeutic potential for oxidative stress in ageing and alzheimer’s disease , 2008, Neurotoxicity Research.

[70]  S. Imai Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases. , 2009, Current pharmaceutical design.

[71]  E. Chini CD38 as a regulator of cellular NAD: a novel potential pharmacological target for metabolic conditions. , 2009, Current pharmaceutical design.

[72]  F. LaFerla,et al.  Nicotinamide Restores Cognition in Alzheimer's Disease Transgenic Mice via a Mechanism Involving Sirtuin Inhibition and Selective Reduction of Thr231-Phosphotau , 2008, The Journal of Neuroscience.

[73]  J. Schneider,et al.  Broad neuroprotective profile of nicotinamide in different mouse models of MPTP‐induced parkinsonism , 2008, The European journal of neuroscience.

[74]  J. Kirkland,et al.  The role of dietary niacin intake and the adenosine-5′-diphosphate-ribosyl cyclase enzyme CD38 in spatial learning ability: is cyclic adenosine diphosphate ribose the link between diet and behaviour? , 2008, Nutrition Research Reviews.

[75]  F. Zipp,et al.  Sirt1 contributes critically to the redox-dependent fate of neural progenitors , 2008, Nature Cell Biology.

[76]  R. de Cabo,et al.  Mechanisms Underlying Caloric Restriction and Lifespan Regulation: Implications for Vascular Aging , 2008, Circulation research.

[77]  M. Seman,et al.  Extracellular NAD and ATP: Partners in immune cell modulation , 2007, Purinergic Signalling.

[78]  C. Mathers,et al.  Global prevalence of dementia: a Delphi consensus study , 2005, The Lancet.

[79]  Julie A Schneider,et al.  Thoughts on B-vitamins and dementia. , 2006, Journal of Alzheimer's disease : JAD.

[80]  Adrian C. Williams,et al.  Nicotinamide: a double edged sword. , 2005, Parkinsonism & related disorders.

[81]  J. Alisky Niacin improved rigidity and bradykinesia in a Parkinson's disease patient but also caused unacceptable nightmares and skin rash—A case report , 2005, Nutritional neuroscience.

[82]  R. Tuma NAD to the rescue , 2005, The Journal of Cell Biology.

[83]  A. Williams,et al.  Parkinson's disease: the first common neurological disease due to auto-intoxication? , 2005, QJM : monthly journal of the Association of Physicians.

[84]  Adrian C. Williams,et al.  Autotoxicity, methylation and a road to the prevention of Parkinson’s disease , 2005, Journal of Clinical Neuroscience.

[85]  A. Williams,et al.  Nicotinamide homeostasis: a xenobiotic pathway that is key to development and degenerative diseases. , 2005, Medical hypotheses.

[86]  J. Milbrandt,et al.  Increased Nuclear NAD Biosynthesis and SIRT1 Activation Prevent Axonal Degeneration , 2004, Science.

[87]  D. Bennett,et al.  Dietary niacin and the risk of incident Alzheimer’s disease and of cognitive decline , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[88]  J. Simon,et al.  Neuroscience. NAD to the rescue. , 2004, Science.

[89]  V. Demarin,et al.  Treatment of Alzheimer's disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study. , 2004, Drugs under experimental and clinical research.

[90]  R. Spector Niacinamide transport through the blood-brain barrier , 2004, Neurochemical Research.

[91]  R. Waring,et al.  High expression of nicotinamide N-methyltransferase in patients with idiopathic Parkinson's disease , 2003, Neuroscience Letters.

[92]  K. Maiese,et al.  Nicotinamide: necessary nutrient emerges as a novel cytoprotectant for the brain. , 2003, Trends in pharmacological sciences.

[93]  Bin Liu,et al.  Role of Microglia in Inflammation-Mediated Neurodegenerative Diseases: Mechanisms and Strategies for Therapeutic Intervention , 2003, Journal of Pharmacology and Experimental Therapeutics.

[94]  R. Waring,et al.  Expression of Nicotinamide N‐Methyltransferase (E.C. 2.1.1.1) in the Parkinsonian Brain , 2002, Journal of neuropathology and experimental neurology.

[95]  S. Yamaguchi,et al.  Nicotinamide-N-methyltransferase is higher in the lumbar cerebrospinal fluid of patients with Parkinson's disease , 2001, Neuroscience Letters.

[96]  K. Maiese,et al.  Nicotinamide: A Nutritional Supplement that Provides Protection Against Neuronal and Vascular Injury. , 2001, Journal of medicinal food.

[97]  P. Bingley,et al.  Safety of high-dose nicotinamide: a review , 2000, Diabetologia.

[98]  B. Everitt,et al.  Age-dependence of malonate-induced striatal toxicity , 2000, Experimental Brain Research.

[99]  C. Ogilvy,et al.  Delayed treatment with nicotinamide (Vitamin B(3)) improves neurological outcome and reduces infarct volume after transient focal cerebral ischemia in Wistar rats. , 2000, Stroke.

[100]  K. Jellinger,et al.  No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia , 2000, Journal of Neural Transmission.

[101]  D. Guastella,et al.  Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[102]  O. Axelson,et al.  Nutritional and occupational factors influencing the risk of Parkinson's disease: A case‐control study in southeastern Sweden , 1999, Movement disorders : official journal of the Movement Disorder Society.

[103]  N. Nishiyama,et al.  3‐Hydroxykynurenine, an Endogenous Oxidative Stress Generator, Causes Neuronal Cell Death with Apoptotic Features and Region Selectivity , 1998, Journal of neurochemistry.

[104]  A. Galione,et al.  Nicotinamide inhibits cyclic ADP-ribose-mediated calcium signalling in sea urchin eggs. , 1996, The Biochemical journal.

[105]  G. Ulm,et al.  Diet and Parkinson's disease II , 1996, Neurology.

[106]  J. Birkmayer Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type. , 1996, Annals of clinical and laboratory science.

[107]  B. Rosen,et al.  Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate , 1994, Annals of neurology.

[108]  P. Debré,et al.  The lymphocyte surface antigen CD38 acts as a nicotinamide adenine dinucleotide glycohydrolase in human T lymphocytes , 1993, European journal of immunology.

[109]  B. Hyman,et al.  Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[110]  B. Hyman,et al.  Age‐Dependent Striatal Excitotoxic Lesions Produced by the Endogenous Mitochondrial Inhibitor Malonate , 1993, Journal of neurochemistry.

[111]  H. Herzog,et al.  Effect of Huntington's and Alzheimer's diseases on the transport of nicotinic acid or nicotinamide across the human blood-brain barrier. , 1991, Advances in experimental medicine and biology.

[112]  Y. Kagawa,et al.  Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. , 1989, Biochemical and biophysical research communications.

[113]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[114]  W. Nicklas,et al.  Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.

[115]  R. Levine,et al.  Hydroxylase cofactor activity in cerebrospinal fluid of normal subjects and patients with Parkinson's disease. , 1979, Science.